Here’s the introduction to their piece
A broad group of marijuana companies, cannabis trade organizations, nonprofits, law firms, doctors, ancillary companies, and activists has joined forces in the hopes of influencing a review by the Biden administration which could result in federal marijuana legalization.
The group, called the Coalition for Cannabis Scheduling Reform, will try to persuade the U.S. Food and Drug Administration and other agencies that marijuana’s decades-long presence on Schedule 1 of the list of controlled substances is simply bad policy. CCSR noted in a press release that there has never been a single death attributed by federal health regulators to a cannabis overdose.
“Yet cannabis is classified as a Schedule 1 controlled substance under federal law, on par with heroin and above methamphetamine, opium, and fentanyl,” CCSR noted in a statement.
“We’re optimistic that the FDA and the administration will listen to the science and the legal arguments, which will inevitably point them to Schedule 3 or lower, or in an ideal case, de-scheduling,” said Bryan Barash, vice president at cannabis tech firm Dutchie and co-chair of CCSR.
Some of the coalition’s members include:
- Multistate operators such as Acreage Holdings, Columbia Care, Cresco Labs, Curaleaf, Green Thumb Industries, PharmaCann, and Verano Holdings.
- Small social equity marijuana businesses such as Housing Works, Smacked, and Union Square Travel Agency.
- Trade associations such as the American Trade Association for Cannabis and Hemp, the National Cannabis Roundtable, the New York CAURD Coalition, and the U.S. Cannabis Council.
- Nonprofits such as the Marijuana Policy Project, Hemp for Victory, the Justus Foundation, the Bronx Community Foundation, and the Weldon Project.